Live market news
Stocks
1672.HK

1672.HK

1672.HKStock

Latest news on 1672.HKranked by Oyticker for market impact

55Impact
Positive2 Oct 2026 · 09:15 UTC · Global · Medium term
Ascletis ASC36_35FDC shows extended dosing interval and weight-loss efficacy in preclinical data
Ascletis presented preclinical data for ASC36_35FDC demonstrating potential for once-monthly to once-quarterly dosing with robust weight-loss effects. The extended dosing interval and efficacy profile may differentiate the candidate in the competitive GLP-1 receptor agonist space.
1672.HKPharmaceuticalsBiotechnology

Oyticker provides market information and analysis for educational purposes. It is not investment advice: you remain responsible for your own decisions.

Latest news on 1672.HKranked by Oyticker for market impact

Ascletis ASC36_35FDC shows extended dosing interval and weight-loss efficacy in preclinical data